Solid implantable devices for sustained drug delivery

Magill, Elizabeth; Demartis, Sara; Gavini, Elisabetta; Permana, Andi Dian; Thakur, Raghu; Adrianto, Muhammad Faris; Waite, David; Glover, Katie; Picco, Camila J.; Korelidou, Anna; Detamornrat, Usanee; Vora, Lalitkumar K.; Li, Linlin; Anjani, Qonita Kurnia; Donnelly, Ryan F.; Domínguez-Robles, Juan; Larrañeta, Eneko

doi:10.1016/j.addr.2023.114950

Cited by 34 publications

(15 citation statements)

References 367 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These dosage forms produce therapeutic effects with lower drug concentrations, minimizing potential side-effects of therapy and offering the opportunity for increased patient compliance. This type of system is also employed to deliver drugs that cannot be administered orally [ 53 , 54 ].…”

Section: Resultsmentioning

confidence: 99%

3D Printing Direct Powder Extrusion in the Production of Drug Delivery Systems: State of the Art and Future Perspectives

Aguilar-de-Leyva,

Casas,

Ferrero

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

The production of tailored, on-demand drug delivery systems has gained attention in pharmaceutical development over the last few years, thanks to the application of 3D printing technology in the pharmaceutical field. Recently, direct powder extrusion (DPE) has emerged among the extrusion-based additive manufacturing techniques. It is a one-step procedure that allows the direct processing of powdered formulations. The aim of this systematic literature review is to analyze the production of drug delivery systems using DPE. A total of 27 articles have been identified through scientific databases (Scopus, PubMed, and ScienceDirect). The main characteristics of the three types of 3D printers based on DPE have been discussed. The selection of polymers and auxiliary excipients, as well as the flowability of the powder mixture, the rheological properties of the molten material, and the printing temperatures have been identified as the main critical parameters for successful printing. A wide range of drug delivery systems with varied geometries and different drug release profiles intended for oral, buccal, parenteral, and transdermal routes have been produced. The ability of this technique to manufacture personalized, on-demand drug delivery systems has been proven. For all these reasons, its implementation in hospital settings in the near future seems promising.

show abstract

Section: Resultsmentioning

confidence: 99%

3D Printing Direct Powder Extrusion in the Production of Drug Delivery Systems: State of the Art and Future Perspectives

Aguilar-de-Leyva,

Casas,

Ferrero

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Systemic chemotherapy, however, has several shortcomings. These include high dosages, hazardous side effects, and frequent treatments 77 . The use of implantable biomedical devices offers several advantages, including sustained and controlled drug release, minimization of drug level fluctuations, extended duration of action, and reduced side effects 77 , 78 .…”

Section: Resultsmentioning

confidence: 99%

In-vivo studies of targeted and localized cancer drug release from microporous poly-di-methyl-siloxane (PDMS) devices for the treatment of triple negative breast cancer

Eluu,

Obayemi,

Salifu

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) treatment is challenging and frequently characterized by an aggressive phenotype and low prognosis in comparison to other subtypes. This paper presents fabricated implantable drug-loaded microporous poly-di-methyl-siloxane (PDMS) devices for the delivery of targeted therapeutic agents [Luteinizing Hormone-Releasing Hormone conjugated paclitaxel (PTX-LHRH) and Luteinizing Hormone-Releasing Hormone conjugated prodigiosin (PG-LHRH)] for the treatment and possible prevention of triple-negative cancer recurrence. In vitro assessment using the Alamar blue assay demonstrated a significant reduction (p < 0.05) in percentage of cell growth in a time-dependent manner in the groups treated with PG, PG-LHRH, PTX, and PTX-LHRH. Subcutaneous triple-negative xenograft breast tumors were then induced in athymic female nude mice that were four weeks old. Two weeks later, the tumors were surgically but partially removed, and the device implanted. Mice were observed for tumor regrowth and organ toxicity. The animal study revealed that there was no tumor regrowth, six weeks post-treatment, when the LHRH targeted drugs (LHRH-PTX and LHRH-PGS) were used for the treatment. The possible cytotoxic effects of the released drugs on the liver, kidney, and lung are assessed using quantitative biochemical assay from blood samples of the treatment groups. Ex vivo histopathological results from organ tissues showed that the targeted cancer drugs released from the implantable drug-loaded device did not induce any adverse effect on the liver, kidneys, or lungs, based on the results of qualitative toxicity studies. The implications of the results are discussed for the targeted and localized treatment of triple negative breast cancer.

show abstract

“…These polymers have been extensively used for the development of drug eluting medical devices. 11–15 Over time, they degrade into non-toxic by products, rendering them compatible with the human body. 16 The use of biodegradable implants may obviate the need for implant removal, enhancing patient well-being while reducing healthcare costs.…”

Section: Introductionmentioning

confidence: 99%

An isocratic RP-HPLC-UV method for simultaneous quantification of tizanidine and lidocaine: application to in vitro release studies of a subcutaneous implant

Picco,

Anjani,

Donnelly

et al. 2024

Anal. Methods

Self Cite

View full text Add to dashboard Cite

show abstract

Solid implantable devices for sustained drug delivery

Cited by 34 publications

References 367 publications

3D Printing Direct Powder Extrusion in the Production of Drug Delivery Systems: State of the Art and Future Perspectives

3D Printing Direct Powder Extrusion in the Production of Drug Delivery Systems: State of the Art and Future Perspectives

In-vivo studies of targeted and localized cancer drug release from microporous poly-di-methyl-siloxane (PDMS) devices for the treatment of triple negative breast cancer

An isocratic RP-HPLC-UV method for simultaneous quantification of tizanidine and lidocaine: application to in vitro release studies of a subcutaneous implant

Contact Info

Product

Resources

About